Cardiovascular Effects of Methotrexate in Rheumatoid Arthritis Revisited

Author(s): Tatyana V. Popkova, Diana S. Novikova, Armen Yuri Gasparyan, Evgeny L. Nasonov

Journal Name: Current Medicinal Chemistry

Volume 22 , Issue 16 , 2015

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Cardiovascular events such as myocardial infarction (MI) and stroke due to enhanced inflammatory atherosclerosis account for increased premature mortality in rheumatoid arthritis (RA). Accumulated evidence suggests that accelerated atherosclerosis and related cardiovascular comorbidities in RA are confounded not only by traditional risk factors (TRF) but also by a number of immune and inflammatory pathways. Since chronic inflammation and autoimmune disorders play a key role in atherosclerosis and related cardiovascular complications in RA, effective suppression of systemic inflammation can be viewed as a strategy for cardiovascular therapy and prevention in this disease. This article overviews some mechanisms of action of methotrexate on TRF, clinical and subclinical manifestations of RA-induced atherosclerosis, and related cardiovascular morbidity and mortality.

Keywords: Atherosclerosis, cardiovascular diseases, inflammation, methotrexate, rheumatoid arthritis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 13 May, 2015
Page: [1903 - 1910]
Pages: 8
DOI: 10.2174/0929867322666150415122039
Price: $65

Article Metrics

PDF: 52